"Our scientists have shown that psychedelics have real potential as medicine, and this new center will help us explore that potential.”
- Paul B. Rothman, M.D., Dean of the Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine.
At John Hopkins' Center for Psychedelic and Consciousness Research, researchers will focus on how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health.
Upcoming studies will determine the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa and alcohol use in people with major depression. The researchers hope to create precision medicine treatments tailored to the specific needs of individual patients.
A 2006 landmark study by John Hopkins paved the way for today's shrooms research center by not ofonly revealing the power of shrooms but of mystical experience ocassioned by the psychoactive ingredient found in magic mushrooms.